Publications by authors named "Cheng-Di Weng"
Article Synopsis
- The study focuses on the effectiveness and safety of a triple-targeted therapy (dabrafenib, trametinib, and osimertinib) for advanced non-small cell lung cancer (NSCLC) patients who developed a V600E mutation after initially responding to EGFR-TKI treatment.
- A multi-center review of 13 NSCLC patients showed promising results, with an objective response rate of 61.5% and a disease control rate of 92.3%, alongside a median progression-free survival of 13.5 months.
- The research also included patient-derived organoids to assess drug response and next-generation sequencing to identify resistance mechanisms, highlighting significant tumor growth inhibition with the triple-targeted therapy compared to other reg
Plasma ddPCR for the detection of amplification in advanced NSCLC patients: a comparative real-world study.
Ther Adv Med Oncol
February 2024
Background: Mesenchymal-epithelial transition () amplification is a crucial oncogenic driver and a resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) of non-small-cell lung cancer (NSCLC). Fluorescence hybridization (FISH) is the gold standard for amplification detection. However, it is inapplicable when tissue samples are unavailable.
View Article and Find Full Text PDF